Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eganelisib in locally advanced HNSCC
NCT03795610Phase 2Completed
- Start
- Mar 2020
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eganelisib in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Adverse Events at 7 weeks. Started Mar 2020; status: completed.
02
Drugs
eganelisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03795610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795610.